Compare Amgen, Inc. (AMGN) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Estee Lauder Companies Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Estee Lauder Companies Inc trades at $82.6 (market cap $29.91B). The key difference: Amgen, Inc. is far larger — about 6.6× Estee Lauder Companies Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | EL | |
|---|---|---|
Market Cap | $196.12B | $29.91B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $119.61 |
52-Week Low | $271.18 | $67.23 |
Enterprise Value | $241.41B | $36.08B |
Dividend Yield | 2.77% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Estée Lauder (EL) trades at $82.66, up 0.82% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported negative net income of -$1.13B in 2025, though it has beaten EPS estimates in recent quarters. Revenue has declined from $17.7B in 2022 to $14.33B in 2025, while debt-to-asset ratio rose to 36.78%.
The outlook is mixed: analyst consensus is a Buy with a $90.60 price target, but high valuation ratios and profitability challenges pose risks. Positive sentiment from news highlights innovation and industry trends, yet financial performance and macroeconomic pressures remain headwinds for near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
